TriSalus Life Sciences, Inc. (TLSI) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | |
| Borrowing debt due after one year | 33.06M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Excluding Current Maturities |
| Total assets | 62.45M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $33.06M | (m) | (m) | $62.45M | (m) |
| 2026-03-31 | (m) | (m) | (m) | $33.08M | (m) | (m) | $70.98M | (m) |
| 2025-12-31 | (m) | (m) | (m) | $33.05M | (m) | (m) | $35.33M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $32.76M | (m) | (m) | $36.46M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $32.27M | (m) | (m) | $41.32M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $31.70M | (m) | (m) | $28.63M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $22.08M | (m) | (m) | $23.97M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $21.68M | (m) | (m) | $27.48M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $21.29M | (m) | (m) | $32.43M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $0.00 | (m) | (m) | $25.73M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |